Key Points
- Nimrata Hunt sold 2,693 shares on Feb. 26 at an average of $661.54 for about $1.78M, trimming her holdings by 11.92% to 19,899 shares (≈$13.16M).
- IDEXX slightly missed EPS ($2.92 vs. $2.93 estimate) but posted revenue of $1.09B, up 14.3% year-over-year, set FY2026 EPS guidance of $14.29–$14.80, and retains a consensus "Moderate Buy" from analysts with a $783.33 average price target despite recent target cuts.
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) EVP Nimrata Hunt sold 2,693 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the sale, the executive vice president directly owned 19,899 shares of the company's stock, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
IDEXX Laboratories Stock Down 0.6%
Shares of IDXX opened at $656.73 on Friday. The company has a market capitalization of $52.29 billion, a P/E ratio of 50.25, a PEG ratio of 4.01 and a beta of 1.67. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business's 50 day simple moving average is $672.95 and its 200-day simple moving average is $668.97. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company's revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a report on Monday, February 9th. BTIG Research decreased their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating on the stock in a research note on Tuesday, February 3rd. UBS Group dropped their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research report on Tuesday, February 3rd. Jefferies Financial Group reiterated a "buy" rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, January 29th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $783.33.
View Our Latest Report on IDEXX Laboratories
Hedge Funds Weigh In On IDEXX Laboratories
Hedge funds have recently added to or reduced their stakes in the stock. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at approximately $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the 2nd quarter worth approximately $30,000. J.Safra Asset Management Corp acquired a new position in IDEXX Laboratories during the third quarter valued at approximately $31,000. Finally, Armstrong Advisory Group Inc. increased its stake in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company's stock valued at $34,000 after purchasing an additional 19 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.
About IDEXX Laboratories
(
Get Free Report)
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
